PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Strides Pharma Approves Demerger from Arco Labs

Last year, Strides Pharma announced the approval from National Company Law Tribunal (NCLT) for OneSource bringing together its specialized businesses.

Arco Lab will incorporate the NewCo to facilitate the proposed demerger.

Strides Pharma is set to demerge from Arco Labs, a global capability centre, the company said in its exchange filing on Wednesday. Board of Directors of Strides Pharma Science Limited (Strides) and Arco Lab in their meeting held today have accorded their in-principle approval for the proposed demerger of Identified Business of Arco Lab, the company stated.

“Arco Lab is an innovative Global Life Sciences Capability Centre offering a wide range of services in life sciences consulting, technology, and business solutions. It is proposed to transfer by way of demerger the Life Sciences and Digital Innovation Capabilities (“Identified Business”) of Arco Lab into a New Company (NewCo). Such NewCo shall focus on Life Sciences and Manufacturing solutions with deep domain knowledge and cutting-edge technology capabilities,” the company stated.

Arco Lab will incorporate the NewCo to facilitate the proposed demerger including undertaking requisite preparatory steps viz., drawing up of the scheme of arrangement, valuation of the identified business, amongst others, it added.

“The proposed structure envisages the NewCo to be a WOS of Strides and there will not be any impact on Strides, financially or otherwise arising out of the proposed restructuring. Requisite disclosures in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be made upon incorporation of the NewCo by Arco Lab and in the further stages of the said Corporate Action,” it said.

Strides Pharma Global Pte. Limited proposed to acquire 100% stake in Amexel Pte. Ltd., Singapore.SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of US $10.

Last year, Strides Pharma announced the approval from National Company Law Tribunal (NCLT) for OneSource bringing together its specialized businesses.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026